• ERT and Bioclinica are now Clario. Find out more about our new name, and why we have come together.

Your using an unsupported browser. Please update to a modern browser for a better experience.

Clinical Trials on Alzheimer’s Disease Conference (CTAD)

November 29, 2022
December 2, 2022
PT
Hilton Union Square - 333 O'Farrell Street - San Francisco, CA 94102, USA

Clario is proud to be a silver sponsor of the 15th annual Clinical Trials on Alzheimer’s Disease conference (CTAD). CTAD is a meeting focused entirely on Alzheimer’s Disease Therapeutic Trials with key leaders in Alzheimer Disease research from Industry and Academia getting together and forming partnerships with the objective of speeding the development of effective treatments to fight the disease.

Schedule a meeting with the Clario team onsite, or visit our virtual booth during the conference to find out more.

Session 1 Information:

Concordance of Visual and Quantitative Analysis for Amyloid PET Imaging With Three 18F Tracers in the CHARIOT-PRO Substudy

Date: Wednesday, November 30th, 2022

Time: 2:40 p.m. PST

Authors: Gerald Novak, Ziad Saad, David Scott, Chi Udeh-Momoh, Luc Bracoud, Craig Ritchie, Lefkos Middleton

Session 2 Information:

Summary of ACR Phantom MRI site qualification findings over 7 years and recommendations moving forward

Date: Thursday, December 1st, 2022

Poster Session: P077

Time: 8:00 a.m. – 6:00 p.m. PST

Authors: Luc Bracoud, Joonmi Oh, Qui Cao, Chris Conklin, Madhura Ingalhalikar, Ha Pham, David Scott, Joyce Suhy

Session 3 Information:

Prevalence of microhemorrhages, superficial siderosis and other MRI abnormalities in a population of cognitively unimpaired older adults from the CHARIOT-PRO study

Date: Thursday, December 1st, 2022

Poster Session: LP59

Time: 8:00 a.m. – 6:00 p.m. PST

Authors: Luc Bracoud , Chi Udeh-Momoh, Ziad Saad, Dimitra Kafetsouli, Emmett Daly, Onah Okoye, Parthenia Giannakopoulou, David Scott, Joyce Suhy, Susan Baker, Gerald Novak, Craig Ritchie, Lefkos Middleton

David Scott headshot

David Scott, PhD

VP, Medical & Scientific Affairs, Neuroscience at Clario

David Scott, Ph.D., is Vice President, Medical and Scientific Affairs at Clario. His aim is to facilitate drug development through standardized measurement of the neural correlates of neurodegenerative and other centrally mediated diseases. As a student at Johns Hopkins University and the University of Michigan, he employed multi-modal imaging approaches including dynamic PET and functional MRI to study the neurobiology of placebo analgesia. At Omneuron, he developed real-time fMRI applications aimed at treating chronic pain, depression and addiction.

Since joining Clario in 2012, David’s focus has been to enable MRI and molecular imaging solutions toward safety, eligibility, and therapeutic efficacy endpoints. He works with radiologists, physicists, software engineers, and operational specialists on the design, execution, analysis, and interpretation of neuroscience clinical trial imaging data. His motivation is to enable neuroimaging to accelerate the delivery of therapeutic benefit to patients around the world.

Luc Bracoud headshot

Luc Bracoud, MSc

Director, Neuroscience at Clario

Luc Bracoud received his Master of Science degree from Ecole Centrale Lyon in 2001. He joined Clario in 2002 as a Project Manager and Research and Development Engineer where he developed various brain MRI image-processing algorithms including image registration, segmentation, DTI, PWI and brain atrophy assessment, and managed large Alzheimer’s disease (AD), Multiple Sclerosis (MS) and Stroke clinical trials. Luc then transitioned to an oversight role where he designs and directs all of Clario’s MRI Neuroscience trials, from a scientific and technical perspective.

Joyce Suhy headshot

Joyce Suhy, PhD

Senior VP, Medical Imaging at Clario

Working in the field of Medical Imaging since 1992, Dr. Suhy has authored numerous journal articles and book chapters in imaging of the brain. Dr. Suhy has lead the design and scientific oversight of Neuroscience clinical trials since 2001, within the following indications: Alzheimer’s disease (AD), Mild Cognitive Impairment, Prodromal AD, Dementia with Lewy Body, Vascular Dementia, Frontotemporal Dementia, Down Syndrome, Huntington’s Disease, Multiple Sclerosis, Parkinson’s disease, Progressive Supranuclear Palsy, Trauma, Brain Tumors, Stroke and Stroke Devices, Intracranial Hemorrhage, Post-Traumatic Stress Disorder, Spinal Cord Injury, CADASIL, Fabry disease, Multiple System Atrophy, Contrast Agents, Pediatric indications, Rare diseases, etc. Dr. Suhy has also participated on several expert panels to advance the use of imaging in clinical trials.